Axsome Therapeutics, Inc. (AXSM) NASDAQ
$93.41 1.66 (1.80%)
Market Cap: $4.48B
As of 09/13/24 09:55 AM EDT. Market open.
Axsome Therapeutics, Inc. (AXSM)
NASDAQ
$93.41
1.66 (1.80%)
Market Cap: $4.48B
As of 09/13/24 09:55 AM EDT. Market open.
Add to Portfolio
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Herriot Tabuteau M.D.
Full Time Employees
589
CEO Compensation (Base)
$750,000
CEO Compensation (Total)
$9.90M
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Herriot Tabuteau M.D.
Full Time Employees
589
CEO Compensation (Base)
$750,000
CEO Compensation (Total)
$9.90M
URL
Address
22 Cortlandt Street, NY, New York, 10007.
PRICE CHART FOR AXSOME THERAPEUTICS, INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$92.33
Previous Close
$91.75
Days Range
$91.72 - $93.69
52 week range
$55.02 - $98.40
Volume
18,860
Avg. Volume (30 days)
580,559
Market Cap
$4.48B
Dividend Yield
-
P/E
(14.20)
Shares Outstanding
48,000,200
Open
$92.33
Previous Close
$91.75
Days Range
$91.72 - $93.69
52 week range
$55.02 - $98.40
Volume
18,860
Avg. Volume (30 days)
580,559
Market Cap
$4.48B
Dividend Yield
-
P/E
(14.20)
Shares Outstanding
48,000,200
FINANCIAL STATEMENTS FOR AXSOME THERAPEUTICS, INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR AXSOME THERAPEUTICS, INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Saad Mark E | Director | Sep 11, 2024 | Option Exercise | $3.67 | 11,016 | 40,429 | 21,018 | Sep 11, 2024, 07:00 PM |
| Saad Mark E | Director | Sep 11, 2024 | Sale | $91.31 | 11,016 | 1,005,871 | 10,002 | Sep 11, 2024, 07:00 PM |
| Jacobson Mark L. | Chief Operating Officer | Aug 09, 2024 | Option Exercise | $4.04 | 47,739 | 192,866 | 53,522 | Aug 09, 2024, 07:27 PM |
| Jacobson Mark L. | Chief Operating Officer | Aug 09, 2024 | Sale | $84.26 | 47,739 | 4,022,488 | 5,783 | Aug 09, 2024, 07:27 PM |
| Jacobson Mark L. | Chief Operating Officer | May 29, 2024 | Option Exercise | $1.30 | 13,693 | 17,801 | 13,693 | May 29, 2024, 08:12 PM |
| Jacobson Mark L. | Chief Operating Officer | May 29, 2024 | Sale | $74.31 | 7,910 | 587,813 | 5,783 | May 29, 2024, 08:12 PM |
| Coleman Mark | Director | May 29, 2024 | Sale | $75.14 | 5,248 | 394,333 | 14,600 | May 29, 2024, 08:11 PM |
| Coleman Mark | Director | May 28, 2024 | Sale | $75.21 | 5,249 | 394,775 | 19,848 | May 29, 2024, 08:11 PM |
| Jacobson Mark L. | Chief Operating Officer | Apr 01, 2024 | Option Exercise | $1.30 | 24,662 | 32,061 | 24,662 | Apr 01, 2024, 06:46 PM |
| Jacobson Mark L. | Chief Operating Officer | Apr 01, 2024 | Sale | $77.24 | 24,662 | 1,904,942 | 0 | Apr 01, 2024, 06:46 PM |
| JEFFS ROGER | Director | Mar 15, 2024 | Option Exercise | $29.91 | 2,347 | 70,199 | 123,103 | Mar 15, 2024, 08:05 PM |
| JEFFS ROGER | Director | Mar 14, 2024 | Option Exercise | $24.01 | 29,976 | 719,787 | 137,732 | Mar 15, 2024, 08:05 PM |
| JEFFS ROGER | Director | Mar 14, 2024 | Sale | $69.70 | 29,976 | 2,089,387 | 120,756 | Mar 15, 2024, 08:05 PM |
| JEFFS ROGER | Director | Mar 15, 2024 | Sale | $71.61 | 2,347 | 168,062 | 120,756 | Mar 15, 2024, 08:05 PM |
| Coleman Mark | Director | Sep 15, 2023 | Option Exercise | $3.67 | 11,016 | 40,429 | 36,113 | Sep 15, 2023, 06:30 PM |
| Coleman Mark | Director | Sep 15, 2023 | Sale | $75.18 | 18,572 | 1,396,189 | 403,856 | Sep 15, 2023, 06:30 PM |
| Coleman Mark | Director | Sep 15, 2023 | Sale | $75.19 | 11,016 | 828,241 | 25,097 | Sep 15, 2023, 06:30 PM |
| Coleman Mark | Director | Jan 03, 2023 | Option Exercise | $1.30 | 17,501 | 22,751 | 25,097 | Jan 04, 2023, 04:11 PM |
| Coleman Mark | Director | Mar 15, 2022 | Option Exercise | $1.30 | 3,496 | 4,545 | 7,596 | Mar 17, 2022, 07:05 AM |
| JEFFS ROGER | Director | Nov 19, 2021 | Buy | $37.30 | 3,950 | 147,350 | 120,756 | Nov 23, 2021, 07:30 AM |
| Pizzie Nick | CHIEF FINANCIAL OFFICER | Nov 18, 2021 | Buy | $34.97 | 428 | 14,968 | 201 | Nov 22, 2021, 07:31 AM |
| Pizzie Nick | CHIEF FINANCIAL OFFICER | Nov 18, 2021 | Buy | $35.50 | 527 | 18,709 | 41,789 | Nov 22, 2021, 07:31 AM |
| Coleman Mark | Director | Nov 18, 2021 | Buy | $35.09 | 1,430 | 50,181 | 422,428 | Nov 22, 2021, 07:30 AM |
| Saad Mark E | Director | Nov 17, 2021 | Buy | $34.53 | 3,000 | 103,597 | 10,002 | Nov 19, 2021, 07:30 AM |
| Saad Mark E | Director | Nov 17, 2021 | Buy | $34.42 | 300 | 10,325 | 100 | Nov 19, 2021, 07:30 AM |
| Coleman Mark | Director | May 12, 2021 | Buy | $58.15 | 500 | 29,075 | 420,998 | May 13, 2021, 07:05 AM |
| Coleman Mark | Director | Jun 29, 2020 | Buy | $78.50 | 650 | 51,025 | 403,698 | Jun 30, 2020, 08:20 AM |
| Pizzie Nick | Chief Financial Officer | Jun 29, 2020 | Buy | $76.64 | 777 | 59,549 | 41,217 | Jun 30, 2020, 08:19 AM |
| JEFFS ROGER | Director | Jan 10, 2020 | Option Exercise | $10.46 | 60,186 | 629,756 | 116,806 | Jan 14, 2020, 04:08 PM |
| Pizzie Nick | Chief Financial Officer | Sep 26, 2019 | Buy | $24.80 | 2,180 | 54,064 | 40,440 | Sep 30, 2019, 07:16 AM |
| JEFFS ROGER | Director | Jul 03, 2019 | Option Exercise | $3.04 | 56,620 | 172,178 | 56,620 | Jul 05, 2019, 07:00 AM |
| Coleman Mark | Director | Jun 26, 2019 | Buy | $23.10 | 15,800 | 364,980 | 668,848 | Jun 27, 2019, 07:18 AM |
| Coleman Mark | Director | Jun 25, 2019 | Buy | $23.25 | 400 | 9,300 | 653,048 | Jun 27, 2019, 07:18 AM |
| Pizzie Nick | Chief Financial Officer | Jun 11, 2019 | Buy | $20.80 | 1,920 | 39,936 | 1,920 | Jun 12, 2019, 07:00 AM |
| Saad Mark E | Director | May 23, 2019 | Buy | $22.33 | 3,500 | 78,155 | 7,002 | May 24, 2019, 07:19 AM |
| Coleman Mark | Director | May 13, 2019 | Buy | $21.44 | 4,650 | 99,696 | 652,648 | May 15, 2019, 07:21 AM |
| Pizzie Nick | Chief Financial Officer | Mar 19, 2019 | Buy | $12.58 | 5,340 | 67,177 | 36,340 | Mar 21, 2019, 07:05 AM |
| Pizzie Nick | Chief Financial Officer | Mar 19, 2019 | Buy | $12.69 | 60 | 761 | 60 | Mar 21, 2019, 07:05 AM |
| Coleman Mark | Director | Mar 19, 2019 | Buy | $12.18 | 5,100 | 62,118 | 5,100 | Mar 21, 2019, 07:05 AM |
| Pizzie Nick | Chief Financial Officer | Jun 19, 2018 | Buy | $3.10 | 31,000 | 96,080 | 31,000 | Jun 20, 2018, 05:00 PM |
| JEFFS ROGER | Director | Mar 29, 2017 | Option Exercise | $4.73 | 42,538 | 201,163 | 46,912 | Mar 30, 2017, 04:31 PM |
| Kaye Randall | Chief Medical Officer | Dec 23, 2015 | Buy | $9.03 | 1,000 | 9,026 | 6,022 | Dec 24, 2015, 01:02 PM |
| Ames Constance | Vice President, Finance | Nov 24, 2015 | Option Exercise | $5.94 | 4,358 | 25,887 | 4,358 | Nov 24, 2015, 04:26 PM |
| Kaye Randall | Chief Medical Officer | Nov 24, 2015 | Option Exercise | $5.40 | 5,022 | 27,119 | 5,022 | Nov 24, 2015, 04:26 PM |
| Coleman Mark | Director | Nov 24, 2015 | Option Exercise | $5.71 | 564,948 | 3,224,166 | 647,998 | Nov 24, 2015, 04:25 PM |
| JEFFS ROGER | Director | Nov 24, 2015 | Option Exercise | $5.94 | 4,374 | 25,982 | 4,374 | Nov 24, 2015, 04:25 PM |
| Saad Mark E | Director | Nov 24, 2015 | Option Exercise | $5.94 | 3,502 | 20,802 | 3,502 | Nov 24, 2015, 04:24 PM |
| TABUTEAU HERRIOT | Chief Executive Officer | Nov 24, 2015 | Option Exercise | $5.94 | 7,229 | 42,940 | 7,229 | Nov 24, 2015, 04:24 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Saad Mark E | Director | 09/11/2024 | 40,429 |
| Saad Mark E | Director | 09/11/2024 | 1,005,871 |
| Jacobson Mark L. | Chief Operating Officer | 08/09/2024 | 192,866 |
| Jacobson Mark L. | Chief Operating Officer | 08/09/2024 | 4,022,488 |
| Jacobson Mark L. | Chief Operating Officer | 05/29/2024 | 17,801 |
| Jacobson Mark L. | Chief Operating Officer | 05/29/2024 | 587,813 |
| Coleman Mark | Director | 05/29/2024 | 394,333 |
| Coleman Mark | Director | 05/28/2024 | 394,775 |
| Jacobson Mark L. | Chief Operating Officer | 04/01/2024 | 32,061 |
| Jacobson Mark L. | Chief Operating Officer | 04/01/2024 | 1,904,942 |
| JEFFS ROGER | Director | 03/15/2024 | 70,199 |
| JEFFS ROGER | Director | 03/14/2024 | 719,787 |
| JEFFS ROGER | Director | 03/14/2024 | 2,089,387 |
| JEFFS ROGER | Director | 03/15/2024 | 168,062 |
| Coleman Mark | Director | 09/15/2023 | 40,429 |
| Coleman Mark | Director | 09/15/2023 | 1,396,189 |
| Coleman Mark | Director | 09/15/2023 | 828,241 |
| Coleman Mark | Director | 01/03/2023 | 22,751 |
| Coleman Mark | Director | 03/15/2022 | 4,545 |
| JEFFS ROGER | Director | 11/19/2021 | 147,350 |
| Pizzie Nick | CHIEF FINANCIAL OFFICER | 11/18/2021 | 14,968 |
| Pizzie Nick | CHIEF FINANCIAL OFFICER | 11/18/2021 | 18,709 |
| Coleman Mark | Director | 11/18/2021 | 50,181 |
| Saad Mark E | Director | 11/17/2021 | 103,597 |
| Saad Mark E | Director | 11/17/2021 | 10,325 |
| Coleman Mark | Director | 05/12/2021 | 29,075 |
| Coleman Mark | Director | 06/29/2020 | 51,025 |
| Pizzie Nick | Chief Financial Officer | 06/29/2020 | 59,549 |
| JEFFS ROGER | Director | 01/10/2020 | 629,756 |
| Pizzie Nick | Chief Financial Officer | 09/26/2019 | 54,064 |
| JEFFS ROGER | Director | 07/03/2019 | 172,178 |
| Coleman Mark | Director | 06/26/2019 | 364,980 |
| Coleman Mark | Director | 06/25/2019 | 9,300 |
| Pizzie Nick | Chief Financial Officer | 06/11/2019 | 39,936 |
| Saad Mark E | Director | 05/23/2019 | 78,155 |
| Coleman Mark | Director | 05/13/2019 | 99,696 |
| Pizzie Nick | Chief Financial Officer | 03/19/2019 | 67,177 |
| Pizzie Nick | Chief Financial Officer | 03/19/2019 | 761 |
| Coleman Mark | Director | 03/19/2019 | 62,118 |
| Pizzie Nick | Chief Financial Officer | 06/19/2018 | 96,080 |
| JEFFS ROGER | Director | 03/29/2017 | 201,163 |
| Kaye Randall | Chief Medical Officer | 12/23/2015 | 9,026 |
| Ames Constance | Vice President, Finance | 11/24/2015 | 25,887 |
| Kaye Randall | Chief Medical Officer | 11/24/2015 | 27,119 |
| Coleman Mark | Director | 11/24/2015 | 3,224,166 |
| JEFFS ROGER | Director | 11/24/2015 | 25,982 |
| Saad Mark E | Director | 11/24/2015 | 20,802 |
| TABUTEAU HERRIOT | Chief Executive Officer | 11/24/2015 | 42,940 |
Load More Insider Transactions
FUNDS WITH A POSITION IN AXSOME THERAPEUTICS, INC.
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 3,299,991 | 0.00601% | 3.27% | Other |
| RA CAPITAL MANAGEMENT, L.P. | 1,000,000 | 1.06% | No change | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 884,895 | 0.00625% | 4.67% | Other |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 730,000 | 0.11% | 41.75% | Other |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 204,699 | 0.16% | Exited | Growth |
| WCM INVESTMENT MANAGEMENT, LLC | 113,345 | 0.02% | 1.57% | Growth At A Reasonable Price |
| CANDRIAM S.C.A. | 75,084 | 0.04% | Exited | Other |
| ALPS ADVISORS INC | 33,417 | 0.02% | Exited | Other |
| D. E. SHAW & CO., INC. | 31,500 (Put) | 0.00237% | No change | Other |
| AQR CAPITAL MANAGEMENT LLC | 12,836 | 0.00158% | -54.6% | Other |
| TUDOR INVESTMENT CORP ET AL | 18,983 | 0.00783% | New | Event Driven, Other |
| OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) | 15,118 | 0.08% | 69.52% | Value |
| OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) | 15,000 (Call) | 0.00292% | New | Value |
| ROYCE & ASSOCIATES LP | 13,000 | 0.00978% | No change | Value |
| D. E. SHAW & CO., INC. | 10,200 (Call) | 0.00077% | No change | Other |
| BALYASNY ASSET MANAGEMENT L.P. | 9,606 | 0.00134% | Exited | Event Driven |
| D. E. SHAW & CO., INC. | 6,334 | 0.00048% | -18.47% | Other |
| FARALLON CAPITAL MANAGEMENT LLC | 4,000 | 0.00152% | No change | Event Driven, Value |
CHANGE IN SHARES OUTSTANDING FOR AXSOME THERAPEUTICS, INC.
STOCK BUYBACKS FOR AXSOME THERAPEUTICS, INC.
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 06/30/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
03/31/2024
0.38%
1Q
12/31/2023
0.47%
2Q
09/30/2023
0.97%
3Q
06/30/2023
8.94%
4Q
03/31/2023
9.30%
5Q
12/31/2022
9.42%
6Q
09/30/2022
14.07%
7Q
06/30/2022
21.73%
8Q
03/31/2022
24.14%
9Q
12/31/2021
25.97%
10Q
09/30/2021
26.25%
11Q
06/30/2021
26.54%
12Q
03/31/2021
27.10%
13Q
12/31/2020
27.36%
14Q
09/30/2020
27.50%
15Q
06/30/2020
28.23%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR AXSOME THERAPEUTICS, INC.
LOADING...